英語ページ

Publications 2005

  1. Kamoto, T., Isogawa, Y., Shimizu, Y., Minamiguchi, S., Kinoshita, H., Kakehi, Y., Mitsumori, K., Yamamoto, S., Habuchi, T., Kato, T., and Ogawa, O. (2005) Association of a genetic polymorphism of the E-cadherin gene with prostate cancer in a Japanese population. Jpn. J. Clin. Oncol., 35, 158-161.
  2. Kataoka, A., Yuasa, T., Kageyama, S., Iwaki, H., Higuchi, K., Tanaka, T., Okada, Y., Yoshiki, T. (2005) Expression of thymidine phosphorylase correlates with microvessel density in prostate cancer. Oncol. Rep., 13, 597-600.
  3. Kimura, S., Naito, H., SEgawa, H., Kuroda, J., Yuasa, T., Sato, K., Yokota, A., Kamitsuji, Y., Kawata, E., Ashihara E, Nakaya Y, Naruoka H, Wakayama T, Nasu K, Asaki T, Niwa T, Hirabayashi, K, Maekawa, T. (2005) NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood, 106. 3948-3954.
  4. Kimura, S., Ito C, Jyoko N, SEgawa, H., Kuroda, J., Okada M, Adachi S, Nakahata T, Yuasa, T., Filho VC, Furukawa H, Maekawa, T. (2005) Inhibition of leukemic cell growth by a novel anti-cancer drug (GUT-70) from Calophyllim brasiliense that acts by induction of apoptosis. Int. J. Cancer, 113, 158-165.
  5. Kimura, S., Yurugi K, SEgawa, H., Kuroda, J., Sato, K., Nogawa, M., Yuasa, T., Egawa, H., Tanaka K, Maekawa, T. (2005) Rapid Quantitation of IgG Antibodies Specific for Blood Group Antigens A and B by Surface Plasmon Resonanse. Transfusion, 45, 56-62.
  6. Matsumoto, S., Kimura, S., Segawa, S., Kuroda, J., Yuasa, T., Sato, K., Nogawa, M., Tanaka F, Maekawa, T., Wada, H. (2005) Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer, 47, 31-39.
  7. Minagawa, S., Ohyama, C., Hatakeyama, S., Tsuchiya, N., Kato, T., Habuchi, T. (2005) Activation of natural killer T cells by alpha-galactosylceramide mediates clearance of bacteria in murine urinary tract infection. J. Urol., 173, 2171-2174.
  8. Miura, M., Satoh, S., Tada, H., Habuchi, T., and Suzuki, T. (2005) Stereoselective metabolism of rabeprazole-thioether to rabeprazole by human liver microsomes. Eur. J. Clin. Pharmacol., 1-5.
  9. Miura, M., Kagaya, H., Tada, H., Sagae, Y., Satoh, S., Habuchi, T., and Suzuki, T. (2005) Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. Xenobiotica, 35, 479-486.
  10. Nogawa, M., Yuasa, T., Kimura, S., Tanaka M, Kuroda, J., Sato, K., Yokota, A., Segawa, S., Toda Y, Kageyama S, Yoshiki, T., Okada, Y., Maekawa, T. (2005) Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J. Clin. Invest., 115, 978-985.
  11. Nogawa, M., Yuasa, T., Kimura, S., Kuroda, J., Sato, K., SEgawa, H., Yokota, A., Maekawa, T. (2005) Monitoring luciferase-labeled cancer cell growth and metastasis in in vivo models. Cancer Lett., 217, 243-253.
  12. Nogawa, M., Yuasa, T., Kimura, S., Kuroda, J., Segawa, H., Sato, K., Koizumi M, Maekawa, T. (2005) Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells. Oncol. Res., 15, 1-9.
  13. Numakura, K., Satoh, S., Tsuchiya, N., Horikawa, Y., Inoue, T., Kakinuma, H., Matsuura, S., Saito, M., Tada, H., Suzuki T and Habuchi, T. (2005) Clinical and Genetic Risk Factors for Posttransplant Diabetes Mellitus in Adult Renal Transplantation Recipients Treated with Tacrolimus. Transplantation, 80, 1419-1424.
  14. Numakura, K., Satoh, S., Tsuchiya, N., Horikawa, Y., Inoue, T., Kakinuma, H., Togashi, H., Matsuura, S., Tada, H., Suzuki T, Habuchi (2005) Incidence, risk factors of clinical characteristics, tacrolimus pharmacokinetics, and related genomic polumorphisms for posttransplant diabetes mellitus in the early stage of renal transplant recipients. Transplant Proc., 37, 1865-1867.
  15. Sato, K., Kimura, S., Segawa, H., Yokota, A., Matsumoto, S., Kuroda, J., Nogawa, M., Yuasa, T., Kiyono Y, Wada, H., Maekawa, T. (2005) Cytotoxic effects of????T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int. J. Cancer, 116, 94-99
  16. Saito, M., Satoh, S., Nossuke Kojima, Hotoshi Tada, Mitsuru Sato, Suzuki, T., Haruki Senoo, Habuchi, T. (2005) Effects of a phenolic compound, resveratrol, on the renal Function and costimulatory adhesion molecule CD86 expression in rat kidneys with ischemia/reperfusion injury. Arch. Histol. Cytol., 68, 41-49.
  17. Satoh, S., Tada, H., Murakami M., Tsuchiya, N., Inoue, T., Togashi, H., Matsuura, S., Hayase Y., Suzuki T., Habuchi, T. (2005) The influence of mycophenolate mofetil versus azathioprine and mycophenolic acid pharmacokinetics on the incidence of acute rejection and infectious complications after renal transplantation. Transplant Proc., 37, 1751-1753.
  18. Satoh, S., Tsuchiya, N., Habuchi, T., Ishiyama T., Seimo, K., Kato, T. (2005) Renal cell and transitional cell carcinoma in a Japanese population undergoing maintenance dialysis. J. Urol., 174, 1749-1753.
  19. Segawa, T., Kamoto, T., Kinoshita, H., Kunishima, Y., Yoshimura, K., Ito, A., Takahashi, T., Higashi, S., Nakamura, E., Nishiyama, H., Ito, N., Yamamoto, S., Habuchi, T., and Ogawa, O. (2005) Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer. Int. J. Clin. Oncol., 10, 333-337.
  20. Segawa, H., Kimura, S., Kuroda, J., Sato, K., Nogawa, M., Yuasa, T., Yokota, A., Hodohara K, Fujiyama Y, Maekawa, T. (2005) The anti-leukemic efficacy of the third generation bisphosphonate ONO5920/YM529. Leuk. Res., 29 451-457.
  21. Segawa, H., Kimura, S., Kuroda, J., Sato, K., Yokota, A., Kawata, E., Kamitsuji, Y., Ashihara E, Yuasa, T., Fujiyama Y, Ottmann OG, Maekawa, T. (2005) Zoledronate synergizes with imatinib mesylate to inhibit Ph+ primary leukaemic cell growth. Br. J. Haematol., 130, 558-560.
  22. Shioji, G., Ezura, Y., Nakajima, T., Ohgaki, K., Fujiwara, H., Kubota, Y., Ichikawa, T., Inoue, K., Shuin, T., Habuchi, T., Ogawa, O., Nishimura, T., and Emi, M. (2005) Nucleotide variations in genes encoding plasminogen activator inhibitor-2 and serine proteinase inhibitor B10 associated with prostate cancer. J. Hum. Genet., 50, 507-515.
  23. Tada, H., Tsuchiya, N., Satoh, S., Kagaya, H., Li, Z., Sato, K., Miura, M., Suzuki, T., Kato, T., and Habuchi, T. (2005) Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc., 37, 1730-1732.
  24. Tsuchiya, N., Satoh, S., Narita, S., Shimoda N., Matsuura, S., Ohyama, C., Sato, K., Kato, T., Ohtani H., Komatsuda A., Habuchi, T. (2005) Successful renal transplantation in the right iliac fossa 2 years after serious deep venous thrombosis in a patient with systemic lupus erythematosus. Int. J. Urol., 12, 912-916.
  25. Tsuchiya, N., Wang, L., Horikawa, Y., Inoue, T., Kakinuma, H., Matsuura, S., Sato, K., Ogawa, O., Kato, T., Habuchi, T. (2005) CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia. Int. J. Oncol., 26, 2252-31.
  26. Wang, L., Mitoma J., Tsuchiya, N., Narita, S., Horikawa, Y., Habuchi, T., Imai A., Ishimura H., Ohyama, C., Fukuda M. (2005) An A/G polymorphism of core 2 branching enzyme gene is associated with prostate cancer. Biochem. Biophys. Res. Commun., 331, 958-963.
  27. Yuasa, T., Tsuji H, Kimura, S., Niwa N, Yurugi K, Egawa, H., Tanaka K, Maruya E, Saji H, Asano H, Maekawa, T. (2005) HLA in Japanese patients with biliary atresia-a retrospective analysis in the patients with living donor liver transplantation-. Hum. Immunl., 66, 290-295.
  28. Yuasa, T., Niwa N, Kimura, S., Tsuji H, Yurugi K, Egawa, H., Tanaka K, Asano H, Maekawa, T. (2005) Intraoperative blood loss during living donor liver transplantation: -an analysis of 635 recipients at a single center-. Transfusion, 45, 879-884.
  29. Yuasa, T., Nogawa, M., Kimura, S., Yokota, A., Sato, K., SEgawa, H., Kuroda, J., Maekawa, T. (2005) A third generation bisphosphonate, minodronic acid (YM529), augments the interferon mediated inhibition of renal cell cancer cell growth both in vitro and in vivo. Clin. Cancer. Res., 11, 853-859.
  30. Li, Z., Tsuchiya, N., Narita, S., Inoue, T., Horikawa, Y., Kakinuma, H., Kato, T., Ogawa, O., Habuchi, T. (2005) CYP3A5 gene polymorphism and risk of prostate cancer in a Japanese population. Cancer Lett., 225, 237-243.

メニューを開く